Eibl-Lindner K H, Liegl R, Wertheimer C, Kampik A
Augenklinik, LMU München, Campus Innenstadt, Mathildenstr. 8, 80336, München, Deutschland,
Ophthalmologe. 2013 Oct;110(10):990-4. doi: 10.1007/s00347-013-2904-0.
The development of an intraocular lens (IOL) as a drug delivery device has been the purpose of numerous preclinical studies and might become a future technology in cataract surgery. There are three techniques of pharmacological IOL modification: surface modification (coating), optic modification (soaking) or haptic modification with a slow-release-system. The therapeutic goals are endophthalmitis, postoperative inflammation and posterior capsule opacification.
将人工晶状体（IOL）开发成一种药物递送装置一直是众多临床前研究的目标，并且可能会成为白内障手术未来的一项技术。有三种药物性人工晶状体修饰技术：表面修饰（涂层）、光学部修饰（浸泡）或采用缓释系统的襻修饰。治疗目标包括眼内炎、术后炎症和后囊膜混浊。
